News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
62,311 Results
Type
Article (3924)
Company Profile (8)
Press Release (58378)
Multimedia
Podcasts (16)
Webinars (6)
Section
Business (25226)
Career Advice (69)
Deals (3882)
Drug Delivery (17)
Drug Development (4544)
Employer Resources (12)
FDA (908)
Job Trends (1148)
News (30150)
Policy (1386)
Tag
2025 Best Places to Work (1)
2026 Best Places to Work (1)
40 Under 40 (1)
Academia (253)
Accelerated approval (2)
ADA (7)
Allergies (15)
Alliances (5262)
ALS (17)
Alzheimer's disease (159)
Antibody-drug conjugate (ADC) (36)
Approvals (934)
Artificial intelligence (150)
ASCO (10)
Autoimmune disease (46)
Automation (12)
Bankruptcy (34)
Belgium (9)
Best Places to Work (811)
BIO (10)
Biologics (9)
BIOSECURE Act (2)
Biosimilars (26)
BioSpace Insights (38)
Biotechnology (11)
Bispecific (2)
Bladder cancer (11)
Brain cancer (6)
Breast cancer (28)
Cancer (392)
Cardiovascular disease (65)
Career advice (68)
Career pathing (6)
CAR-T (39)
CDC (1)
CDMO (27)
Cell therapy (104)
Cervical cancer (1)
Clinical research (3907)
Collaboration (281)
Commercialization (5)
Compensation (47)
Complete response letters (5)
COVID-19 (165)
CRISPR (11)
CRO (1)
C-suite (263)
Cystic fibrosis (19)
Data (556)
Decentralized trials (1)
Denatured (8)
Depression (15)
Dermatology (11)
Diabetes (46)
Diagnostics (653)
Digital health (12)
Diversity (2)
Diversity, equity & inclusion (2)
Drug discovery (94)
Drug pricing (15)
Duchenne muscular dystrophy (12)
Earnings (4918)
Editorial (8)
Employer resources (11)
ESMO (12)
Events (6187)
Executive appointments (234)
Eye disease (2)
FDA (1164)
Fragile X (1)
Friedreich's ataxia (2)
Frontotemporal dementia (3)
Funding (1036)
Gene editing (24)
Generative AI (16)
Gene therapy (74)
GLP-1 (83)
Government (160)
Guidances (31)
Healthcare (1316)
Hematology (7)
HIV (4)
Huntington's disease (3)
IgA nephropathy (5)
Immunology and inflammation (34)
Immuno-oncology (8)
Indications (11)
Infectious disease (194)
Inflammatory bowel disease (22)
Inflation Reduction Act (4)
Influenza (7)
Intellectual property (25)
Interviews (6)
IPO (1810)
IRA (8)
Job creations (323)
Job search strategy (61)
JPM (10)
Kidney disease (24)
Labor market (20)
Layoffs (46)
Leadership (5)
Legal (286)
Licensing (7)
Liver cancer (7)
Longevity (7)
Lung cancer (41)
Lung diease (1)
Lymphoma (23)
Machine learning (11)
Management (4)
Manufacturing (126)
Marketing (1)
MASH (38)
Medical device (1368)
Medtech (1404)
Melanoma (25)
Mergers & acquisitions (2229)
Metabolic disorders (156)
mRNA (27)
Multiple sclerosis (5)
Multispecific (1)
NASH (4)
Netherlands (7)
Neurodegenerative disease (57)
Neuropsychiatric disorders (13)
Neuroscience (309)
Neurotech (1)
NextGen: Class of 2026 (969)
Non-profit (307)
Now hiring (3)
Obesity (69)
Opinion (62)
Ovarian cancer (17)
Pain (18)
Pancreatic cancer (7)
Parkinson's disease (34)
Partnered (7)
Patents (35)
Patient recruitment (86)
Patient selection (7)
Peanut (8)
People (9394)
Peptides (7)
Pharmaceutical (4)
Phase 1 (1248)
Phase 2 (1795)
Phase 3 (1129)
Pipeline (812)
Policy (33)
Postmarket research (118)
Preclinical (661)
Press Release (6)
Prostate cancer (22)
Psychedelics (7)
Radiopharmaceuticals (45)
Rare diseases (100)
Real estate (600)
Recruiting (6)
Regenerative medicine (2)
Regulatory (1271)
Reports (10)
Research institute (183)
Resumes & cover letters (9)
Rett syndrome (5)
RNA editing (2)
Schizophrenia (8)
Series A (280)
Series B (201)
Sickle cell disease (5)
Special edition (5)
Spinal muscular atrophy (2)
Sponsored (2)
Startups (2242)
Supply chain (6)
Switzerland (2)
Tariffs (4)
Tax incentives (1)
The Weekly (8)
Vaccines (43)
Venture capital (148)
Weight loss (35)
Women's health (14)
Women in leadership (1)
Worklife (1)
Date
Last 7 days (55)
Last 30 days (228)
Last 365 days (2342)
2026 (2151)
2025 (2491)
2024 (2995)
2023 (3156)
2022 (5600)
2021 (4950)
2020 (4822)
2019 (4561)
2018 (3619)
2017 (3105)
2016 (2599)
2015 (3032)
2014 (2165)
2013 (1775)
2012 (1905)
2011 (2129)
2010 (2222)
Location
Africa (70)
Alabama (7)
Alaska (2)
Arizona (25)
Arkansas (5)
Asia (4261)
Australia (532)
California (1259)
Canada (1044)
China (137)
Colorado (30)
Connecticut (49)
Delaware (19)
Europe (9425)
Florida (81)
Georgia (53)
Hawaii (2)
Idaho (5)
Illinois (70)
India (29)
Indiana (31)
Iowa (2)
Japan (68)
Kansas (8)
Kentucky (7)
Louisiana (7)
Maine (6)
Maryland (82)
Massachusetts (739)
Michigan (22)
Minnesota (38)
Mississippi (1)
Missouri (20)
Montana (2)
Nebraska (1)
Nevada (22)
New Hampshire (8)
New Jersey (204)
New Mexico (6)
New York (253)
North Carolina (161)
North Dakota (1)
Northern California (633)
Ohio (47)
Oklahoma (5)
Oregon (5)
Pennsylvania (246)
Puerto Rico (3)
Rhode Island (6)
South America (99)
South Carolina (10)
Southern California (482)
Tennessee (14)
Texas (124)
United States (3664)
Utah (53)
Virginia (28)
Washington D.C. (2)
Washington State (66)
West Virginia (1)
Wisconsin (22)
62,311 Results for "ttp ventus".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
TTP Group Announces the Sale of LEX Diagnostics
April 20, 2026
·
2 min read
Press Releases
Ventus Therapeutics Enters into a Collaboration and License Agreement with Genentech to Discover and Develop Small-Molecule Medicines Using Ventus’ ReSOLVE® Platform
October 22, 2025
·
3 min read
Press Releases
Ventus Therapeutics Announces Nomination of VENT-04, a First-in-Class, Oral, Small-Molecule Caspase-4/5 Inhibitor, as a Development Candidate
January 8, 2026
·
3 min read
Press Releases
Ventus Therapeutics to Present at Morgan Stanley 23rd Annual Global Healthcare Conference
September 5, 2025
·
1 min read
Press Releases
Ventus Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of VENT-03, a Novel Small Molecule cGAS Inhibitor, in Patients with Lupus
December 11, 2025
·
4 min read
Genetown
Ventus Therapeutics to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference
Ventus Therapeutics, Inc announced today that its President and Chief Executive Officer, Marcelo Bigal, M.D., Ph.D., will present at the 2024 Bloom Burton & Co. Healthcare Investor Conference.
April 8, 2024
·
2 min read
Press Releases
Ventus Therapeutics to Present at 2025 Bloom Burton & Co. Healthcare Investor Conference
April 29, 2025
·
1 min read
Press Releases
Ventus Therapeutics Appoints Mona Kotecha, M.D., as Chief Medical Officer
February 19, 2025
·
2 min read
Drug Development
Ventus Therapeutics Announces Results from Phase 1 Clinical Trial of VENT-02, a Novel, Orally Administered, Brain-Penetrant NLRP3 Inhibitor
Ventus Therapeutics today announced results from its Phase 1 clinical trial of VENT-02, a novel, oral, brain-penetrant NLRP3 inhibitor.
April 17, 2024
·
7 min read
Drug Development
Ventus Therapeutics Announces First Participant Dosed in Clinical Study with an NLRP3 Inhibitor Licensed Exclusively to Novo Nordisk
Ventus Therapeutics, Inc. today announced that its partner, Novo Nordisk, has successfully dosed the first participant in a Phase 1 clinical study for NNC6022-0001 (formerly known as VENT-01).
May 3, 2024
·
6 min read
1 of 6,232
Next